Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_assertion type Assertion NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_head.
- NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_assertion description "[Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_provenance.
- NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_assertion evidence source_evidence_literature NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_provenance.
- NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_assertion SIO_000772 21892211 NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_provenance.
- NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_assertion wasDerivedFrom befree-2016 NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_provenance.
- NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_assertion wasGeneratedBy ECO_0000203 NP921453.RAMwFgLys7E4ZioopDvRri9G-Wv2MYvY-0z5qY0P6in8A130_provenance.